Amedisys Company Profile (NASDAQ:AMED)

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys Inc (NASDAQ:AMED) announced its quarterly earnings results on Wednesday, July, 26th. The company reported $0.62 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.50 by $0.12. The company earned $378.80 million during the quarter, compared to the consensus estimate of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. Amedisys's revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.42 earnings per share. View Amedisys' Earnings History.

Amedisys is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Amedisys.

9 brokers have issued twelve-month target prices for Amedisys' stock. Their predictions range from $50.00 to $60.00. On average, they expect Amedisys' share price to reach $56.00 in the next twelve months. View Analyst Ratings for Amedisys.

Here are some recent quotes from research analysts about Amedisys stock:

• 1. According to Zacks Investment Research, "Over the last month, Amedisys has steadily traded above the Zacks categorized Medical-Outpnt/Hm Care industry. Market is particularly positive on the company’s consistent and stellar Home Health division’s performance with solid organic growth in Medicare and non-Medicare revenues. We are also upbeat about the company’s initiative for strategically fit merger and acquisition activities, the most recent deal being East Tennessee Personal Care Service. The company’s strong cash position further bolsters our confidence in the stock. However, CMS’ recently proposed Home Health rule in 2017 proved grossly unfavorable for Amedisys indicating gloomy scenario ahead. Also, Escalation in operating expenses and margin contractions continue to raise concern." (5/2/2017)
• 2. Jefferies Group LLC analysts commented, "We are excited about AMED's 2017 outlook given our view that the company's Q4 performance (margin-driven earnings beat) foreshadows accelerating realization of benefits from its recently-completed IT rollout that should translate into strong earnings power and stock upside. Additionally, AMED's strong balance sheet and robust FCF, coupled with its $100MM EBITDA deal pipeline, should translate to an active year for accretive, upside-driving acquisitions." (3/1/2017)
• 3. Mizuho analysts commented, "Bumps? What bumps? AMED produced 4Q16 SS home health admit growth, nice margin gains and 15% upside to our adj. EBITDA estimate. For '17E, AMED seems poised to realize $40+mm in actual cost savings, admit growth in HH and continued strong growth in hospice, enough to more than offset a $17 mm hit from HH pricing to achieve EBITDA growth of 28%+ in '17E. But the not-so-cheap stock price "knows" that even though we have no guidance yet and a brand new management team. So we reset our PT at $50 to reflect market re-rating, strong results and the prospect of the real, new AMED emerging in 2017." (3/1/2017)

Some companies that are related to Amedisys include ICU Medical (ICUI), Insulet Corporation (PODD), NuVasive (NUVA), Portola Pharmaceuticals (PTLA), Cantel Medical Corp. (CMD), INC Research Holdings (INCR), AveXis (AVXS), Sage Therapeutics (SAGE), LivaNova PLC (LIVN), Hutchison China MediTech Limited (HCM), FibroGen (FGEN), Juno Therapeutics (JUNO), Globus Medical (GMED), Penumbra (PEN), Agios Pharmaceuticals (AGIO), BeiGene (BGNE), Intercept Pharmaceuticals (ICPT) and Ligand Pharmaceuticals Incorporated (LGND).

Amedisys' management team includes the folowing people:

• Paul B. Kusserow, President, Chief Executive Officer, Director
• Gary D. Willis, Chief Financial Officer
• Christopher T. Gerard, Chief Operating Officer
• Lawrence R. Pernosky, Chief Human Resource Officer
• Scott G. Ginn, Chief Accounting Officer
• Michael Paul North, Chief Information Officer
• David B. Pearce, Chief Compliance Officer
• David L. Kemmerly, General Counsel
• Stephen E. Seim, Chief Strategy Officer
• Susan Sender, Chief Clinical Operations Officer

Amedisys' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.30%), Vanguard Group Inc. (7.05%), FMR LLC (5.09%), William Blair Investment Management LLC (4.32%), American Century Companies Inc. (3.49%) and Wells Fargo & Company MN (3.38%). Company insiders that own Amedisys stock include Bruce D Perkins, David B Pearce, Jake L Netterville, Lawrence R Pernosky, North Tide Capital, Llc and Scott G Ginn. View Institutional Ownership Trends for Amedisys.

Amedisys' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Wells Fargo & Company MN, William Blair Investment Management LLC, BlackRock Inc., Voya Investment Management LLC, Goldman Sachs Group Inc., Monarch Partners Asset Management LLC and Sapience Investments LLC. Company insiders that have sold Amedisys stock in the last year include David B Pearce, Jake L Netterville, Lawrence R Pernosky and Scott G Ginn. View Insider Buying and Selling for Amedisys.

Amedisys' stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Balyasny Asset Management LLC, TimesSquare Capital Management LLC, Timpani Capital Management LLC, Acadian Asset Management LLC, Castleark Management LLC, Foundry Partners LLC and AHL Partners LLP. View Insider Buying and Selling for Amedisys.

Shares of Amedisys can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Amedisys stock can currently be purchased for approximately $50.12.